Shire PLC continues to build out its hereditary angioedema franchise, announcing positive results for its Cinryze follow-on SHP616 as it also works to file for regulatory approval of its next-generation HAE prophylactic agent lanadelumab.
On Sept. 11, Shire announced that SHP616 met the primary endpoint and all other endpoints in the Phase III SAHARA...